Menu Search
Equities

Leoclan Co Ltd

7681:TYO

Leoclan Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)974.00
  • Today's Change39.00 / 4.17%
  • Shares traded5.00k
  • 1 Year change+7.39%
  • Beta1.1735
Data delayed at least 20 minutes, as of Nov 15 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Leoclan Co Ltd's revenues fell -25.64% from 26.63bn to 19.80bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 271.31m to 136.06m, a -49.85% decrease.
Gross margin13.22%
Net profit margin0.78%
Operating margin0.89%
Return on assets1.22%
Return on equity2.44%
Return on investment2.38%
More ▼

Cash flow in JPYView more

In 2024, Leoclan Co Ltd did not generate a significant amount of cash. However, Cash Flow from Investing totalled 100.75m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 33.08m in cash from operations while cash used for financing totalled 97.23m.
Cash flow per share42.93
Price/Cash flow per share22.63
Book value per share943.51
Tangible book value per share931.02
More ▼

Balance sheet in JPYView more

Leoclan Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio2.42
Quick ratio2.40
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in JPY

Year on year, growth in earnings per share excluding extraordinary items dropped -49.91%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
EPS growth(5 years)-30.05
EPS (TTM) vs
TTM 1 year ago		-49.96
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.